About Atlanthera
Atlanthera is a Healthcare company based in Saint-herblain (France) founded in 2010. Small molecule drugs for bone diseases and tumors are developed. Atlanthera has raised $1.11 million across 1 funding round from investors including GO CAPITAL. Its focus areas include Life Sciences, Oncology, Drugs and Bone Cancer.
Company details
Atlanthera was founded in 2010 as a subsidiary of Atlanta Group and is based in Saint Herblain, France. Operations are centered in the pharmaceutical sector, where small molecule drugs for bone diseases, particularly tumors, are developed. Vectorization techniques are employed to direct active pharmaceutical ingredients specifically to bone tissue, enabling local delivery of targeted molecules. A portfolio of such new molecules has been established to support these treatments.
- Headquarters Saint-herblain, France
- SectorsHealthcare
- Email••••••••
- Website atlanthera.com
- Social LinkedIn X YouTube
- Total Equity Funding$1.11M (USD)
in 1 rounds
- Latest Funding Round$1.11M (USD), Seed
Apr 2014
- Investors
Apps and channels of Atlanthera
its YouTube channel ATLANTHERA COMPANY has 4 subscribers.
Funding Insights of Atlanthera
Atlanthera has successfully raised a total of $1.11M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.11 million completed in April 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.11M
- Total Rounds 1
- Last Round Seed — $1.11M
- First Round $1.11M
(Apr 2014)
- Investors Count 1
All 1 funding rounds of Atlanthera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2014 | $1.11M | Seed | – | – |
1 investors in total: 1 institutional.
Investors in Atlanthera
Atlanthera has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include GO CAPITAL.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward multiple sectors. | 2003 | gocapital.fr | Rennes, France |
Investor details for Atlanthera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Atlanthera
2 dated milestones of Atlanthera across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Atlanthera is founded.
- Funding First funding round of $1.1M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Atlanthera
Atlanthera was founded in 2010 and raised its 1st funding round 4 years after it was founded.
Atlanthera is headquartered in Saint-herblain, France. It is registered at Saint-herblain, Pays De La Loire, France.
Atlanthera is a funded company, having raised a total of $1.11M across 1 funding round to date. The company's 1st funding round was a Seed of $1.11M, raised on Apr 2014.
Atlanthera was founded in 2010 as a subsidiary of Atlanta Group and is based in Saint Herblain, France. Operations are centered in the pharmaceutical sector, where small molecule drugs for bone diseases, particularly tumors, are developed. Vectorization techniques are employed to direct active pharmaceutical ingredients specifically to bone tissue, enabling local delivery of targeted molecules. A portfolio of such new molecules has been established to support these treatments.
Atlanthera has 1 investor. Key investors include GO CAPITAL.